Frédérique Chaperon

2.4k total citations · 1 hit paper
22 papers, 1.9k citations indexed

About

Frédérique Chaperon is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, Frédérique Chaperon has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cellular and Molecular Neuroscience, 7 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Frédérique Chaperon's work include Neuroscience and Neuropharmacology Research (7 papers), Receptor Mechanisms and Signaling (6 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Frédérique Chaperon is often cited by papers focused on Neuroscience and Neuropharmacology Research (7 papers), Receptor Mechanisms and Signaling (6 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Frédérique Chaperon collaborates with scholars based in Switzerland, Germany and France. Frédérique Chaperon's co-authors include Marie-Hélène Thiébot, Philippe Soubrié, Martine Poncelet, Jeanne Maruani, Gérard Le Fur, M. Arnone, Alain Puech, C. Gentsch, Kevin H. McAllister and Kurt Lingenhoehl and has published in prestigious journals such as Science, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Frédérique Chaperon

20 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors

1997 502 citations M. Arnone, Jeanne Maruani et al. Psychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédérique Chaperon Switzerland	16	1.3k	975	470	317	195	22	1.9k
María Scherma Italy	26	1.3k 1.0×	1.2k 1.2×	530 1.1×	250 0.8×	176 0.9×	67	2.1k
Miquel Martín Spain	19	1.4k 1.1×	971 1.0×	457 1.0×	384 1.2×	153 0.8×	24	1.9k
David G. Stouffer United States	16	1.2k 0.9×	581 0.6×	397 0.8×	325 1.0×	129 0.7×	27	1.6k
Patricia Tagliaferro Argentina	21	1.6k 1.2×	1.7k 1.7×	331 0.7×	487 1.5×	215 1.1×	33	2.5k
Anna Lisa Muntoni Italy	30	2.3k 1.7×	1.6k 1.7×	788 1.7×	588 1.9×	217 1.1×	55	3.1k
Martine Daoust France	28	1.5k 1.1×	456 0.5×	534 1.1×	225 0.7×	200 1.0×	75	2.3k
Brady K. Atwood United States	23	1.4k 1.0×	1.1k 1.1×	694 1.5×	430 1.4×	195 1.0×	55	2.6k
Antonio Luchicchi Netherlands	22	888 0.7×	503 0.5×	545 1.2×	332 1.0×	105 0.5×	35	1.6k
Arnau Busquets-García Spain	22	1.1k 0.8×	1.2k 1.3×	329 0.7×	590 1.9×	135 0.7×	39	1.9k
Nagore Puente Spain	24	1.4k 1.0×	1.2k 1.2×	362 0.8×	594 1.9×	182 0.9×	55	1.9k

Countries citing papers authored by Frédérique Chaperon

Since Specialization

Citations

This map shows the geographic impact of Frédérique Chaperon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédérique Chaperon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédérique Chaperon more than expected).

Fields of papers citing papers by Frédérique Chaperon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédérique Chaperon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédérique Chaperon. The network helps show where Frédérique Chaperon may publish in the future.

Co-authorship network of co-authors of Frédérique Chaperon

This figure shows the co-authorship network connecting the top 25 collaborators of Frédérique Chaperon. A scholar is included among the top collaborators of Frédérique Chaperon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédérique Chaperon. Frédérique Chaperon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barba, Pere, Mi Kwon, Julia Weinmann‐Menke, et al.. (2024). POS0046 PRELIMINARY RESULTS OF AN OPEN-LABEL, MULTICENTRE, PHASE 1/2 STUDY TO ASSESS SAFETY, EFFICACY AND CELLULAR KINETICS OF YTB323 (RAPCABTAGENE AUTOLEUCEL), A RAPIDLY MANUFACTURED CAR T-CELL THERAPY TARGETING CD19 ON B CELLS, FOR SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 83. 327–328. 5 indexed citations

Barba, Pere, Mi Kwon, Julia Weinmann‐Menke, et al.. (2024). LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus. SHILAP Revista de lepidopterología. A170.2–A171.

Wong, Edwin, Carla Nester, Teresa Cavero, et al.. (2021). Iptacopan, a Novel Oral Complement Factor B (FB) Inhibitor, Significantly Reduces Proteinuria and C3 Deposit Scores in Native and Transplanted Kidneys C3 Glomerulopathy (C3G) Patients. Journal of the American Society of Nephrology. 32(10S). B8–B8. 8 indexed citations

Laurent, Didier, Lorcan Walsh, Amir Muaremi, et al.. (2020). Relationship between tendon structure, stiffness, gait patterns and patient reported outcomes during the early stages of recovery after an Achilles tendon rupture. Scientific Reports. 10(1). 20757–20757. 27 indexed citations

Laurent, Didier, Lorcan Walsh, Amir Muaremi, et al.. (2019). Relationship between recovery of tendon biomechanics, gait and patient function after Achilles tendon rupture. Osteoarthritis and Cartilage. 27. S473–S473.

Feuerbach, Dominik, Nicole Pezous, H. Weiss, et al.. (2014). AQW051, a novel, potent and selectiveα7 nicotinicAChreceptor partial agonist: pharmacological characterization and phaseIevaluation. British Journal of Pharmacology. 172(5). 1292–1304. 27 indexed citations

Fendt, Markus, Stefan Imobersteg, Daniel Peterlik, et al.. (2013). Differential roles of mGlu7 and mGlu8 in amygdala-dependent behavior and physiology. Neuropharmacology. 72. 215–223. 33 indexed citations

Chaperon, Frédérique, Markus Fendt, Peter H. Kelly, et al.. (2012). Gastrin-Releasing Peptide Signaling Plays a Limited and Subtle Role in Amygdala Physiology and Aversive Memory. PLoS ONE. 7(4). e34963–e34963. 17 indexed citations

Jacobson, Laura H., S. Renee Commerford, Frédérique Chaperon, et al.. (2011). Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity. Naunyn-Schmiedeberg s Archives of Pharmacology. 384(6). 565–581. 6 indexed citations

10.

Rupprecht, Rainer, Gerhard Rammes, Daniela Eser, et al.. (2009). Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects. Science. 325(5939). 490–493. 272 indexed citations

11.

Fendt, Markus, Stefan Imobersteg, Kurt Lingenhöhl, et al.. (2009). Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology. 206(2). 291–301. 55 indexed citations

12.

Feuerbach, Dominik, Kurt Lingenhoehl, Hans-Rudolf Olpe, et al.. (2008). The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology. 56(1). 254–263. 103 indexed citations

13.

Cryan, John F., Peter H. Kelly, Frédérique Chaperon, et al.. (2004). Behavioral Characterization of the Novel GABAB Receptor-Positive Modulator GS39783 (N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): Anxiolytic-Like Activity without Side Effects Associated with Baclofen or Benzodiazepines. Journal of Pharmacology and Experimental Therapeutics. 310(3). 952–963. 173 indexed citations

14.

Chaperon, Frédérique, et al.. (2003). Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit.. PubMed. 14(5-6). 477–87. 44 indexed citations

15.

Duarte, Christine W., et al.. (2003). Effects of a Dopamine D3 Receptor Ligand, BP 897, on Acquisition and Expression of Food-, Morphine-, and Cocaine-induced Conditioned Place Preference, and Food-seeking Behavior in Rats. Neuropsychopharmacology. 28(11). 1903–1915. 67 indexed citations

16.

Chaperon, Frédérique, Mark D. Tricklebank, Liliane Unger, & H.C. Neijt. (2003). Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors. Neuropharmacology. 44(8). 1047–1053. 53 indexed citations

17.

Chaperon, Frédérique & Marie-Hélène Thiébot. (1999). Behavioral Effects of Cannabinoid Agents in Animals. PubMed. 13(3). 243–281. 256 indexed citations

18.

Chaperon, Frédérique, Philippe Soubrié, Alain Puech, & Marie-Hélène Thiébot. (1998). Involvement of central cannabinoid (CB 1 ) receptors in the establishment of place conditioning in rats. Psychopharmacology. 135(4). 324–332. 238 indexed citations

19.

Arnone, M., Jeanne Maruani, Frédérique Chaperon, et al.. (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology. 132(1). 104–106. 502 indexed citations breakdown →

20.

Chaperon, Frédérique, et al.. (1996). Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behavioural Pharmacology. 7(1). 105–105. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact